Logo image of ABVX

ABIVAX SA-ADR (ABVX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ABVX - US00370M1036 - ADR

117.1 USD
+0.3 (+0.26%)
Last: 1/16/2026, 8:00:00 PM
116.98 USD
-0.12 (-0.1%)
After Hours: 1/16/2026, 8:00:00 PM
Fundamental Rating

1

Overall ABVX gets a fundamental rating of 1 out of 10. We evaluated ABVX against 528 industry peers in the Biotechnology industry. Both the profitability and financial health of ABVX have multiple concerns. ABVX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year ABVX has reported negative net income.
  • In the past year ABVX has reported a negative cash flow from operations.
  • ABVX had negative earnings in each of the past 5 years.
  • In the past 5 years ABVX always reported negative operating cash flow.
ABVX Yearly Net Income VS EBIT VS OCF VS FCFABVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • The Return On Assets of ABVX (-146.87%) is worse than 83.71% of its industry peers.
Industry RankSector Rank
ROA -146.87%
ROE N/A
ROIC N/A
ROA(3y)-70.48%
ROA(5y)-60.32%
ROE(3y)-451.51%
ROE(5y)-460.64%
ROIC(3y)N/A
ROIC(5y)N/A
ABVX Yearly ROA, ROE, ROICABVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ABVX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABVX Yearly Profit, Operating, Gross MarginsABVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, ABVX has more shares outstanding
  • The number of shares outstanding for ABVX has been increased compared to 5 years ago.
  • Compared to 1 year ago, ABVX has a worse debt to assets ratio.
ABVX Yearly Shares OutstandingABVX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ABVX Yearly Total Debt VS Total AssetsABVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 16.74 indicates that ABVX is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 16.74, ABVX belongs to the best of the industry, outperforming 87.31% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 16.74
ROIC/WACCN/A
WACCN/A
ABVX Yearly LT Debt VS Equity VS FCFABVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

  • A Current Ratio of 0.77 indicates that ABVX may have some problems paying its short term obligations.
  • ABVX has a Current ratio of 0.77. This is amonst the worse of the industry: ABVX underperforms 87.88% of its industry peers.
  • A Quick Ratio of 0.77 indicates that ABVX may have some problems paying its short term obligations.
  • ABVX's Quick ratio of 0.77 is on the low side compared to the rest of the industry. ABVX is outperformed by 87.50% of its industry peers.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.77
ABVX Yearly Current Assets VS Current LiabilitesABVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 18.52% over the past year.
EPS 1Y (TTM)18.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-69.31%

3.2 Future

  • The Earnings Per Share is expected to grow by 35.84% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 175.58% on average over the next years. This is a very strong growth
EPS Next Y-3.44%
EPS Next 2Y32.6%
EPS Next 3Y-2.16%
EPS Next 5Y35.84%
Revenue Next Year91.53%
Revenue Next 2Y16.32%
Revenue Next 3Y246.09%
Revenue Next 5Y175.58%

3.3 Evolution

ABVX Yearly Revenue VS EstimatesABVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
ABVX Yearly EPS VS EstimatesABVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • ABVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABVX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABVX Price Earnings VS Forward Price EarningsABVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABVX Per share dataABVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2 -2.5

4.3 Compensation for Growth

  • A cheap valuation may be justified as ABVX's earnings are expected to decrease with -2.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.6%
EPS Next 3Y-2.16%

More info and screens

0

5. Dividend

5.1 Amount

  • ABVX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ABIVAX SA-ADR

NASDAQ:ABVX (1/16/2026, 8:00:00 PM)

After market: 116.98 -0.12 (-0.1%)

117.1

+0.3 (+0.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-15
Earnings (Next)03-23
Inst Owners41.18%
Inst Owner Change0.01%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap9.11B
Revenue(TTM)N/A
Net Income(TTM)-176.24M
Analysts85.71
Price Target130.14 (11.14%)
Short Float %3.1%
Short Ratio1.59
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.17%
PT rev (3m)20.03%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.7%
EPS NY rev (3m)-7.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.65
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-2.03
FCFYN/A
OCF(TTM)-2.02
OCFYN/A
SpS0
BVpS-0.72
TBVpS-1.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -146.87%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-70.48%
ROA(5y)-60.32%
ROE(3y)-451.51%
ROE(5y)-460.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.64%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.77
Quick Ratio 0.77
Altman-Z 16.74
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)54.18%
Cap/Depr(5y)310.65%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.26%
EPS Next Y-3.44%
EPS Next 2Y32.6%
EPS Next 3Y-2.16%
EPS Next 5Y35.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-69.31%
Revenue Next Year91.53%
Revenue Next 2Y16.32%
Revenue Next 3Y246.09%
Revenue Next 5Y175.58%
EBIT growth 1Y-35.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.57%
EBIT Next 3Y14.09%
EBIT Next 5Y40.7%
FCF growth 1Y-141.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-142.43%
OCF growth 3YN/A
OCF growth 5YN/A

ABIVAX SA-ADR / ABVX FAQ

What is the fundamental rating for ABVX stock?

ChartMill assigns a fundamental rating of 1 / 10 to ABVX.


What is the valuation status of ABIVAX SA-ADR (ABVX) stock?

ChartMill assigns a valuation rating of 0 / 10 to ABIVAX SA-ADR (ABVX). This can be considered as Overvalued.


How profitable is ABIVAX SA-ADR (ABVX) stock?

ABIVAX SA-ADR (ABVX) has a profitability rating of 0 / 10.


Can you provide the financial health for ABVX stock?

The financial health rating of ABIVAX SA-ADR (ABVX) is 2 / 10.